deutsch
High-Tech Biotechnology
for fighting cancer
ScheBo® • Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics and drug development.
ScheBo® • Biotech AG is developing novel cancer therapies for the treatment of various solid tumours and their metastases.
Continuous innovation, strong customer focus and creative problem solving have made ScheBo® • Biotech AG a worldwide leading manufacturer of unique products.
ScheBo® • Biotech AG is developing novel cancer therapies for the treatment of various solid tumours and their metastases.
Continuous innovation, strong customer focus and creative problem solving have made ScheBo® • Biotech AG a worldwide leading manufacturer of unique products.
ScheBo® • Biotech AG
- independent
- worldwide distribution network
- exclusive and superior technologies and products
- innovative and unique clinical diagnostic products
- international research network
AEO-Certificate
The Main Customs Office of Giessen, Germany issued an AEO-F Certificate (Authorized Economic Operator – Customs Simplifications plus Security and Safety) to ScheBo Biotech AG on September 30, 2011.
read...
read...
Lecture DDW 2011: New molecular markers: M2-PK
Lecture of Prof. Dr. Sybille Mazurek on WEO/OMED Colorectal Cancer Screening Committee Meeting DDW 2011.
read...
read...
Biomarker ′M2-PK′ Identified as Key Enzyme in Cancer Diagnosis and Therapy
Ground Breaking Findings on Understanding Cancer Published in ′Science′
read...
read...
Video: Focus 2010 lecture on M2-PK
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
read...
read...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
read...
read...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
read...
read...